In its Q2 2026 investor letter, Riverwater Micro Opportunities Strategy highlighted Iradimed Corporation (NASDAQ:IRMD).
Iradimed Corporation (NASDAQ:IRMD) is a medical device company focusing on developing MRI-compatible intravenous infusion pump systems and patient monitoring systems
On July 24, 2026, Iradimed Corporation (NASDAQ:IRMD) closed at $94.49 per share, reflecting a market capitalization of $1.21 billion. Iradimed Corporation (NASDAQ:IRMD) posted a one-month return of 0.45%, while its shares gained 65.45% over the past 52 weeks. Riverwater Micro Opportunities Strategy stated the following regarding Iradimed Corporation (NASDAQ:IRMD) in its Q2 2026 investor update: “Several sales reflected valuation and sizing discipline.
We trimmed Iradimed Corporation (NASDAQ:IRMD) in early May: the position had grown beyond 5% of the portfolio, near-term earnings comparisons are demanding, and the valuation was extended, though the fundamental story remains intact as the company’s new IV pump configurations carry list prices more than double the prior generation.” Iradimed Corporation (NASDAQ:IRMD) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 20 hedge fund portfolios held Iradimed Corporation (NASDAQ:IRMD) at the end of the first quarter, up from 19 in the previous quarter. While we acknowledge the potential of Iradimed Corporation (NASDAQ:IRMD) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.